SCHEMBL8937619

SCHEMBL8937619

CCCOc1cccc(/C(=C/C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
CYP1A2 P05177 1/20 0.58
HSD17B10 Q99714 2/20 0.52
TP53 P04637 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
HPGD P15428 1/20 0.46
SLC29A1 Q99808 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
DRD2 P14416 1/20 0.46
DRD3 P35462 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937623 1.00 ALDH1A1 (0.58) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937626 1.00 ALDH1A1 (0.58) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937373 0.93 ALDH1A1 (0.60) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937368 0.93 ALDH1A1 (0.60) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937786 0.92 ALDH1A1 (0.50) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937277 0.92 ALDH1A1 (0.50) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937280 0.92 ALDH1A1 (0.50) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937601 0.90 HPGD (0.60) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937598 0.90 HPGD (0.60) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2
SCHEMBL8937541 0.90 ALDH1A1 (0.59) ALDH1A1CYP1A2HSD17B10TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed